Biosplice Therapeutics Raises $ 120 M in Equity Funding

Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and others are among the investors in this latest round, which also includes established investor support.

FREMONT, CA: Biosplice Therapeutics (Biosplice), a clinical-stage biotechnology company that is developing therapeutics for major diseases based on alternative pre-mRNA splicing, announced that it has raised 120 million dollars in equity funding from a new biotechnology investment syndicate. Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and others are among the investors in this latest round, which also includes established investor support. Joy Ghosh, Ph.D., of Eventide Asset Management, and Gur Roshwalb, MD, of aMoon will join the company’s Board of Directors as part of the financing.

“We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice,” said CevdetSamikoglu, Chief Executive Officer of Biosplice. “This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need.”

Biosplice is designing small-molecule therapeutics that are first-in-class, based on the cutting-edge technology of alternative pre-mRNA splicing. Biosplice has elucidated novel biology connecting CLK/DYRK kinases to the therapeutic control of alternative splicing, based on foundational discoveries in Wnt pathway modulation. Alternative splicing is a crucial biological process that controls the diversity of proteins in a cell, which determines the cell’s form and function. Within the cellular command and control center, the Biosplices target class controls the selection of tissue-specific mRNA splice sites, rendering them attractive, druggable targets.

Joy Ghosh, Ph.D., of Eventide Asset Management, added, “Biosplices alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. We are particularly excited by lorecivivint, which has the potential to be a first-in-class medicine that could confer both symptomatic and disease-modifying benefits to hundreds of millions of osteoarthritis sufferers worldwide.”